Oxaloacetate Highlighted in Annals of Family Medicine Discussion on ME/CFS Treatment Gaps
Aktie
A recent article in the Annals of Family Medicine highlights an important issue for people living with ME/CFS: many potentially helpful treatment options remain underused in general medical care.
The study reviewed records from 571 patients with ME/CFS who were referred to a specialty clinic between 2018 and 2022. Researchers found that, outside of medications commonly used for pain and anxiety, many therapies discussed by ME/CFS specialists were not widely used before patients reached specialty care.
This matters because ME/CFS is a complex, multisystem disease marked by profound fatigue, post-exertional malaise, unrefreshing sleep, cognitive symptoms, and orthostatic intolerance. Since the COVID-19 pandemic, the number of people experiencing ME/CFS-like illness has increased significantly, making education around treatment options more urgent than ever.
One noteworthy inclusion was oxaloacetate, which was mentioned among treatment approaches discussed in the context of ME/CFS care. For those of us at Oxaloacetate CFS™, this recognition is meaningful because it reflects growing attention to energy metabolism as an important area of ME/CFS research and symptom management.
Many people with ME/CFS describe a profound disruption in energy production, recovery, and exertion tolerance. Oxaloacetate has been studied for its role in cellular energy metabolism, and its inclusion in conversations around ME/CFS treatment options points to the need for broader clinician awareness of emerging approaches.
The study also found that 72.2% of patients reported using at least one dietary supplement, suggesting that many patients are already seeking additional ways to manage symptoms. The authors concluded that better education for clinicians about available treatment options and treatment guides may improve care for this debilitating disease.
For patients, this research reinforces an important message: ME/CFS deserves serious medical attention, informed clinical guidance, and continued investment in research.
We are encouraged to see oxaloacetate included in this broader conversation and hope this publication helps more clinicians become aware of the full range of options being explored for ME/CFS care.